Trusted Resources: News & Meetings
Latest announcements and gatherings
Breakthrough Treatment for Thyroid Eye Disease
For those with severe inflammation from thyroid eye disease, the treatment options historically are limited and often require surgical removal of some of the bones or fat in the eye socket.
That is, until earlier this year when a new medication became available.
Dr. Madina Falcone, an oculoplastics and orbital reconstructive surgeon at UConn Health, says thyroid eye disease’s manner of development is complex and not completely understood.
The FDA approved the first drug for the treatment of thyroid eye disease, teprotumumab, earlier this year, sold under the trade name Tepezza.
“Simply put, Tepezza binds to specialized receptors in the tissues of the eye socket and blocks them, thereby decreasing the inflammation in the orbit,” Falcone says.
myBinderRelated Content
-
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
-
Coping Psychologically with Thyroid Eye Diseasehttps://www.youtube.com/watch?v=A-pjRWHj...
-
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
Shannath Louise Merbs, MD, PhD, FACSShannath Louise Merbs is a fellowship-tr...
-
Raymond Douglas, MD, PhDDr. Raymond Douglas is the Director of t...
-
Jack Ronald Wall, PhDJack Ronald Wall is a Professor of Medic...
-
Michael Kazim, MDMichael Kazim is Clinical Professor of o...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google